Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.

Narrative review of amylin-based therapies for obesity

“This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.”

Long-acting amylin-based therapies demonstrated clinically meaningful weight loss with favorable tolerability

“More recently, long‐acting amylin‐based therapies, including cagrilintide, eloralintide, petrelintide, MET‐233i, ABBV‐295, and AZD6234, as well as combination approaches such as cagrilintide with semaglutide and zenagamtide, have demonstrated clinically meaningful weight loss with generally favorable tolerability profiles.”

Combination of cagrilintide and semaglutide produced approximately 22% weight loss at 68 weeks

“In large phase 3 clinical trials, this combination produced mean body‐weight reductions of approximately 22% after 68 weeks of treatment [34].”